随机临床试验:口服牛磺酸补充剂对比安慰剂可减少慢性肝病患者的肌肉痉挛
本研究为双盲、随机对照、交叉、牛磺酸剂量可变试验,纳入每周至少发生3次肌肉痉挛的慢性肝病患者49例,30例完成方案。每日口服2克牛磺酸相比安慰剂可减少痉挛频率、缩短持续时间并降低严重程度,且未报告不良副作用。作者认为牛磺酸应被视为管理慢性肝病患者肌肉痉挛的安全有效干预措施。
要点
- 每日口服2克牛磺酸相比安慰剂减少痉挛频率(每两周减少7次,P=0.03)。
- 每日口服2克牛磺酸相比安慰剂缩短痉挛持续时间(每两周减少89分钟,P=0.03)。
- 每日口服2克牛磺酸相比安慰剂降低痉挛严重程度(Likert量表降低1.4单位,P<0.004)。
核心结论
- 每日口服2克牛磺酸补充剂可在慢性肝病患者中产生肌肉痉挛频率、持续时间和强度的临床显著减少。
- 作者认为牛磺酸应被视为管理慢性肝病患者肌肉痉挛的安全有效干预措施。
研究设计与样本
- 双盲、随机对照、交叉、牛磺酸剂量可变试验,纳入每周经历三次或以上肌肉痉挛的慢性肝病患者。
- 49例患者入组,30例完成方案;因缺乏结局数据,未能完成方案者未纳入最终分析。
- 参与者平均年龄54.7岁,70%为男性。
- 每名参与者接受牛磺酸补充剂或安慰剂4周后交叉至另一组。
- 主要结局数据由参与者记录肌肉痉挛的频率、持续时间和强度。
主要发现
- 口服牛磺酸补充剂使血清牛磺酸水平升高(P < 0.001)。
- 牛磺酸补充剂未报告相关不良副作用。
- 接受每日2克牛磺酸的患者相比安慰剂,痉挛频率减少(每两周减少7次,P = 0.03)。
- 接受每日2克牛磺酸的患者相比安慰剂,痉挛持续时间缩短(每两周减少89分钟,P = 0.03)。
- 接受每日2克牛磺酸的患者相比安慰剂,痉挛严重程度降低(Likert量表降低1.4单位,P < 0.004)。
临床怎么用
- 作者认为牛磺酸应被视为管理慢性肝病患者肌肉痉挛的安全有效干预措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Painful muscle cramps occur in the majority of patients with cirrhosis impacting significantly on quality of life and sleep patterns. They are frequently unrecognised or overlooked. Current management is based on anecdotal evidence or case study reports. AIM: To investigate the effect of oral taurine supplementation on frequency, duration, and intensity of muscle cramps in patients with chronic liver disease. METHODS: Patients with chronic liver disease who experienced three or more muscle cramps/week were enrolled in a double-blinded, randomised control, crossover, taurine dose-variable study. Each participant received either taurine supplementation or placebo for 4 weeks then crossed to the alternative arm. Primary outcome data for frequency, duration, and intensity of muscle cramps was recorded by participants. Participants recorded frequency, duration, and location of muscle cramps. Biochemical parameters, including serum taurine and methionine levels, were measured at each time point. Linear mixed models were used to analyse outcomes. RESULTS: Forty-nine patients were enrolled in the study and 30 patients completed the protocol. Participants who were unable to complete the protocol were not included in the final analysis due to the absence of outcome data. The mean age of participants was 54.7 years and 70% were males. Oral taurine supplementation increased serum taurine levels (P < 0.001). There were no adverse side effects associated with taurine supplementation. Participants receiving 2 g taurine/d experienced a reduction in cramp frequency (seven cramps fewer/fortnight, P = 0.03), duration (89 minutes less/fortnight P = 0.03), and severity (1.4 units less on a Likert scale P < 0.004) compared to placebo. CONCLUSIONS: Oral supplementation with 2 g taurine/d results in a clinically significant reduction in the frequency, duration, and intensity of muscle cramps in patients with chronic liver disease. Taurine should be considered as a safe and effective intervention in the management of muscle cramps in individuals with chronic liver disease. This study was registered with the Australian New Zealand Clinical Trials Register: ACTRN12612000289819.
引用
- Vidot H, Cvejic E, Carey S, et al. Randomised clinical trial: oral taurine supplementation versus placebo reduces muscle cramps in patients with chronic liver disease. Aliment Pharmacol Ther. 2018. PMID: 30136291. doi:10.1111/apt.14950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。